Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Illumina stock | 321.26

Own Illumina stock in just a few minutes.

Posted

Fact checked

Illumina, Inc is a diagnostics & research business based in the US. Illumina shares (ILMN) are listed on the NASDAQ and all prices are listed in US Dollars. Illumina employs 7,700 staff and has a trailing 12-month revenue of around USD$3.4 billion.

How to buy shares in Illumina

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Illumina. Find the stock by name or ticker symbol: ILMN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Illumina reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$321.26, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Illumina, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Illumina. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Illumina's share price?

Since the stock market crash in March caused by coronavirus, Illumina's share price has had significant positive movement.

Its last market close was USD$321.26, which is 7.88% up on its pre-crash value of USD$295.94 and 63.26% up on the lowest point reached during the March crash when the shares fell as low as USD$196.78.

If you had bought USD$1,000 worth of Illumina shares at the start of February 2020, those shares would have been worth USD$810.76 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,095.50.

Illumina share price

Use our graph to track the performance of ILMN stocks over time.

Illumina shares at a glance

Information last updated 2020-10-20.
Latest market close USD$321.26
52-week range USD$196.78 - USD$404.2
50-day moving average USD$323.708
200-day moving average USD$342.2267
Wall St. target price USD$294.07
PE ratio 69.8737
Dividend yield N/A (0%)
Earnings per share (TTM) USD$4.676

Buy Illumina shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Illumina stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Illumina price performance over time

Historical closes compared with the close of $321.26 from 2020-10-19

1 week (2020-11-20) 6.80%
1 month (2020-10-27) -0.15%
3 months (2020-08-27) -8.50%
6 months (2020-05-27) -11.70%
1 year (2019-11-27) 0.10%
2 years (2018-11-27) -0.16%
3 years (2017-11-27) 43.52%
5 years (2015-11-27) 73.13%

Is Illumina under- or over-valued?

Valuing Illumina stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Illumina's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Illumina's P/E ratio

Illumina's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 70x. In other words, Illumina shares trade at around 70x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Illumina's PEG ratio

Illumina's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.013. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Illumina's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Illumina's EBITDA

Illumina's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.2 billion.

The EBITDA is a measure of a Illumina's overall financial performance and is widely used to measure a its profitability.

Illumina financials

Revenue TTM USD$3.4 billion
Operating margin TTM 29.69%
Gross profit TTM USD$2.5 billion
Return on assets TTM 8.75%
Return on equity TTM 15.58%
Profit margin 20.68%
Book value $31.253
Market capitalisation USD$47.4 billion

TTM: trailing 12 months

Shorting Illumina shares

There are currently 3.9 million Illumina shares held short by investors – that's known as Illumina's "short interest". This figure is 3.2% down from 4.0 million last month.

There are a few different ways that this level of interest in shorting Illumina shares can be evaluated.

Illumina's "short interest ratio" (SIR)

Illumina's "short interest ratio" (SIR) is the quantity of Illumina shares currently shorted divided by the average quantity of Illumina shares traded daily (recently around 2.2 million). Illumina's SIR currently stands at 1.79. In other words for every 100,000 Illumina shares traded daily on the market, roughly 1790 shares are currently held short.

However Illumina's short interest can also be evaluated against the total number of Illumina shares, or, against the total number of tradable Illumina shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Illumina's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Illumina shares in existence, roughly 30 shares are currently held short) or 0.0305% of the tradable shares (for every 100,000 tradable Illumina shares, roughly 31 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Illumina.

Find out more about how you can short Illumina stock.

Illumina's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Illumina.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Illumina's total ESG risk score

Total ESG risk: 9.18

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Illumina's overall score of 9.18 (as at 10/01/2020) is excellent – landing it in it in the 2nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Illumina is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Illumina's environmental score

Environmental score: 2.22/100

Illumina's environmental score of 2.22 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Illumina's social score

Social score: 2.6/100

Illumina's social score of 2.6 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Illumina's governance score

Governance score: 5.36/100

Illumina's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Illumina is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Illumina's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Illumina scored a 1 out of 5 for controversy – the highest score possible, reflecting that Illumina has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Illumina, Inc was last rated for ESG on: 2020-10-01.

Total ESG score 9.18
Total ESG percentile 2.42
Environmental score 2.22
Environmental score percentile 2
Social score 2.6
Social score percentile 2
Governance score 5.36
Governance score percentile 2
Level of controversy 1

Illumina share dividends

We're not expecting Illumina to pay a dividend over the next 12 months.

Have Illumina's shares ever split?

Illumina's shares were split on a 2:1 basis on 23 September 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Illumina shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Illumina shares which in turn could have impacted Illumina's share price.

Illumina share price volatility

Over the last 12 months, Illumina's shares have ranged in value from as little as $196.78 up to $404.2. A popular way to gauge a stock's volatility is its "beta".

ILMN.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Illumina's is 0.8924. This would suggest that Illumina's shares are less volatile than average (for this exchange).

Illumina overview

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site